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regions of the gene. Hence, subtle changes at the level of 
gene expression might be relevant for the etiopathology 
of schizophrenia. Behavioural phenotypes obtained with a 
mouse model of slightly increased gene dosage and electro-
physiological investigations with human risk-allele carriers 
revealed an overlapping spectrum of schizophrenia-relevant 
endophenotypes. Most prominently, early information pro-
cessing and higher cognitive functions appear to be associ-
ated with TCF4 risk genotypes. Moreover, a recent human 
study unravelled gene × environment interactions between 
TCF4 risk alleles and smoking behaviour that were specifi-
cally associated with disrupted early information process-
ing. Taken together, TCF4 is considered as an integrator 
(‘hub’) of several bHLH networks controlling critical steps 
of various developmental, and, possibly, plasticity-related 
transcriptional programs in the CNS and changes of TCF4 
expression also appear to affect brain networks important 
for information processing. Consequently, these findings 
support the neurodevelopmental hypothesis of schizo-
phrenia and provide a basis for identifying the underlying 
molecular mechanisms.
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Introduction
Schizophrenia is still an unsolved genetic enigma. Although 
the disease is clearly heritable and great effort has been 
undertaken in the past decades to elucidate the genetic 
basis of this disorder, no major risk genes that would be 
suitable for prediction of the illness have been identified. 
Abstract Schizophrenia is a genetically complex disease 
considered to have a neurodevelopmental pathogenesis and 
defined by a broad spectrum of positive and negative symp-
toms as well as cognitive deficits. Recently, large genome-
wide association studies have identified common alleles 
slightly increasing the risk for schizophrenia. Among the 
few schizophrenia-risk genes that have been consistently 
replicated is the basic Helix-Loop-Helix (bHLH) tran-
scription factor 4 (TCF4). Haploinsufficiency of the TCF4 
(formatting follows IUPAC nomenclature: TCF4 protein/
protein function, Tcf4 rodent gene cDNA mRNA, TCF4 
human gene cDNA mRNA) gene causes the Pitt-Hopkins 
syndrome—a neurodevelopmental disease characterized by 
severe mental retardation. Accordingly, Tcf4 null-mutant 
mice display developmental brain defects. TCF4-associated 
risk alleles are located in putative coding and non-coding 
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The reason for this failure might arise from complex mul-
tigenetic interactions of risk alleles with minor individual 
contributions. It is also likely that a disease entity ‘schizo-
phrenia’ does not exist behind the phenomenology-based 
disease classifications, which have been useful for the clini-
cal requirements but not for biological research. Thus, in 
the following text and for improved readability, the word 
‘schizophrenia’ actually means ‘schizophrenia-spectrum 
disorder’. Nevertheless, in recent years, some interesting 
and replicable findings with population-wide significance 
have suggested that variations in a few genes might serve 
as risk markers in a subgroup of schizophrenia patients. 
Among the most validated genes is the basic Helix-Loop-
Helix (bHLH) transcription factor 4 (TCF4). The preclini-
cal and clinical findings regarding the connection between 
the TCF4 gene and schizophrenia will be reviewed and 
discussed.
The basic‑Helix‑Loop‑Helix protein TCF4
TCF4 belongs to the superfamily of bHLH transcription 
factors that can act as a transcriptional repressor or acti-
vator in a context-specific fashion [1]. The bHLH domain 
comprises the basic region mediating DNA binding and a 
dimerization interface provided by the HLH domain with 
two amphipathic helices separated by an unstructured loop 
region forming left-turned four-helix bundles in dimers [2, 
3]. bHLH proteins are involved in various developmental 
processes, including control of proliferation, determina-
tion of cell fate and specifications, but have also been 
shown to be transcriptional integrators of adaptive cellular 
processes in terminally differentiated cells [1, 4–6]. TCF4 
(also known as e2-2/SeF2, ITF2, Me2) is an ubiquitously 
expressed protein and subgrouped with two additional so-
called e-proteins, TCF3/e2A and TCF12/HeB, as class I 
bHLH factors [2] (for complete lists of gene name assign-
ments, see, e.g. http://www.ihop-net.org or http://www.ncb
i.nlm.nih.gov/gene). Ubiquitously expressed class I bHLH 
factors (TCF3, TCF4 and TCF12) are capable of forming 
homo-dimers and hetero-dimers with numerous cell-type-
specific (or class II) bHLH and dominant-negative (or class 
v) HLH factors of the ID family (ID1-4) that lack a basic 
region and are therefore inhibiting DNA binding by seques-
tering bHLH factors [1].
Of particular practical importance is that the acronym or 
gene name alias TCF4 is unfortunately also widely used for 
T Cell Factor 4 (official gene symbol TCF7L2). TCF7L2 
belongs to the high mobility group (HMG) family of tran-
scription factors and interacts with β-catenin of the wNT 
signalling pathway [7]. Therefore, great care should be 
taken when using software tools that automatically anno-
tate key words from literature entries with ‘TCF4’ and 
when manually scanning the ‘TCF4’ literature. In conse-
quence, the ‘bHLH-TCF4-schizophrenia- and Pitt-Hopkins 
Syndrome (PTHS)’-related literature is likely to be contam-
inated by some false associations and authors, and review-
ers and readers should be sensible to this fact. we could not 
find evidence for a function of the bHLH factor TCF4 in 
glia/oligodendrocyte development, which has unfortunately 
been mentioned in several previous reviews.
Dimeric bHLH complexes bind to partially palindro-
mic short DNA elements called ephrussi-boxes (e-boxes) 
with the core sequence 5′-CANNTG-3′ located in regula-
tory regions [8]. For structural reasons, individual bHLH 
proteins display a preference towards particular e-box 
half-sites, which, however, does not necessarily predict the 
exact binding site of a given hetero-dimer which can even 
vary at different sites of the genome [9]. Class II bHLH 
factors cannot form homo-dimers and exert their transcrip-
tional function only in concert with a class I or e-protein 
such as TCF4 [1]. TCF4 may thus exert pleiotropic func-
tions depending on its dimerisation partner(s) at a given 
developmental stage and in a particular cell type. In conse-
quence, TCF4 functions have been shown to be modulated 
by spatio-temporal expression patterns of its various inter-
action partners, differences in DNA-binding specificities, 
post-translational modifications and associated co-factors 
[10–13].
Mammalian e-proteins have been shown to at least par-
tially complement for each other, and gene dosage effects 
have been described in lymphocyte development that fur-
ther enhances the pleiotropic functions of these genes and 
complicates the assignment of dedicated roles for indi-
vidual e-proteins [14, 15]. In contrast to mammals, only 
one e-protein is found in Drosophila melanogaster and 
Caenorhabditis elegans, i.e. daughterless (da) and helix-
loop-helix protein 2 (hlh-2), respectively. Still, the corre-
sponding mutants revealed multiple phenotypes including 
deficits in nervous system development indicating phylo-
genetic conservation of e-protein functions [16–18]. The 
human and mouse genes coding for TCF4 are located on 
chromosome 18 in both species. The mouse gene Tcf4 
encompasses >360 kB (chr 18e2, forward strand) and 
the human TCF4 >440 kB (chr 18q21.2, reverse strand) 
(www.ensembl.org, rel. 72). More than 18 coding splice 
variants with alternative N-termini have been described 
in humans [10], and the ensembl genome browser 
(www.ensembl.org, rel. 72) lists 43 potentially protein 
encoding variants with the majority including the bHLH 
domain. Moreover, Sepp and colleagues [10] subgrouped 
22 exons that are alternatively spliced, particularly in the 
5′ region with multiple alternative transcription initiation 
sites. Up to date, two putative antisense and one microRNA 
transcripts (miR4529) have been annotated on the opposite 
strand within the human TCF4 locus (none so far in the 
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mouse) potentially indicating regulation at the RNA level of 
increased complexity in the human genome. TCF4 mRNA 
abundance levels and/or control of translation may be regu-
lated by complementary microRNAs (miRs) shown to bind 
to the 3′ region of TCF4 transcripts including the schizo-
phrenia-associated risk factor miR-137 as well as miR-155 
and miR-204 [19–22], while the number of predicted and, 
however, so far experimentally not validated binding sites 
for additional miRs is much longer [23]. Besides the C-ter-
minal located bHLH domain, TCF4 shares with the other 
class I/e-proteins additional regions of homology includ-
ing two more N-terminally located transcriptional activa-
tion domains (AD1 and AD2) [24, 25]. These domains have 
been shown to provide protein–protein-interaction surfaces 
to recruit chromatin remodelling complexes and transcrip-
tional co-factors such as CBP/p300 [26, 27]. Moreover, 
TCF4 may be part of a SwI/SNF chromatin-remodelling 
complex which might be of relevance for the etiopathology 
of schizophrenia [28]. A knockdown of endogenous TCF4 
in the human neuroblastoma cell line SH-SY5Y by siRNA 
altered the expression of multiple genes corresponding to 
various signalling pathways and affected cell survival, epi-
thelial to mesenchymal transition and neuronal differentia-
tion [29]. The siRNA approach yielded a highly efficient 
reduction of endogenous TCF4 protein to levels below 
20 %. Therefore, these findings that were obtained in a pro-
liferating neuroblastoma cell line could be of relevance for 
PTHS, where a loss-of-function of TCF4 is most probable. 
Nonetheless, it is unclear which bHLH interaction partners/
dimeric complexes were affected in SH-SY5Y cells, e.g. 
affecting neuronal differentiation properties of this cell line 
and whether these processes mimic developmental defects 
causing PTHS in vivo. Because of the presumably very 
subtle effects by the extragenic common alleles in TCF4 
that have been associated with an increased risk of schizo-
phrenia, mechanistic studies with relevance for schizophre-
nia are most likely technically more challenging.
In summary, the mammalian class I bHLH protein TCF4 
can be considered as an integrator (‘hub’) of several bHLH 
networks controlling critical steps of various develop-
mental and possibly also plasticity-related transcriptional 
programs in the CNS (see Fig. 1). The deregulated splic-
ing events and/or mRNA misexpression or altered stabil-
ity of one or more distinct TCF4 protein isoform(s), which 
could be of particular relevance for schizophrenia, are still 
unknown.
Schizophrenia
The main symptoms of schizophrenia can be distin-
guished into three major domains: (1) positive symp-
toms such as hallucinations, perceptual disturbances, 
delusional phenomena and formal thought disorder; (2) 
negative symptoms mostly presented as flat affect, pov-
erty of speech, avolition, anhedonia, lack of motivation and 
inappropriate emotional responses; and (3) cognitive dys-
function including impairment of attention, memory, social 
cognition and executive functions [30]. The highest risk 
period for developing schizophrenia is during young adult-
hood, while both sexes are equally affected by the disorder, 
although the age of onset is typically younger for men than 
women [31–33]. Although incidence rates vary depending 
on classification criteria, schizophrenia affects approxi-
mately 1 % of the population across cultures [34, 35]. 
Individuals with parents or siblings suffering from schizo-
phrenia have an increased risk for developing the disorder 
(8–12 %). For monozygotic twins, the concordance rate is 
approximately 50 % [36, 37]. The elevated familial inci-
dence of schizophrenia strongly indicates that there must 
be a genetic contribution to the disorder, although the fact 
that concordance rates for monozygotic twins are lower 
than 100 % suggests that environmental factors are also 
considerably involved. Thus, it is likely that a combination 
of genetic risk and environmental factors are required for 
the disorder to develop [37]. Initially, family-based linkage 
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Fig. 1  Different bHLH transcription factors direct central nervous 
system (CNS) development at embryonic stages and may be involved 
in adult brain plasticity. Inhibitory bHLH factors (HeS1, ID1) and 
proneural factors ATOH1, ASCL1 and NeUROG1,2 as well as e-pro-
teins TCF3 and TCF12 are involved in early developmental stages. 
The temporal expression patterns and mutational analyses of the neu-
rogenic differentiation factors (NeUROD1,2 and 6) and inhibitors of 
differentiation ID2 and ID4 suggest instead a function in later stages 
of neuronal differentiation and in the adult CNS. The spatiotemporal 
expression pattern of Tcf4 overlaps substantially with all other bHLH 
factors involved in brain development. Moreover, TCF4 is capable of 
forming hetero-dimers with most involved neuron expressed bHLH 
factors although direct evidence is thus far only available for NeU-
ROD1 and -2 (as indicated by a solid line in contrast to dashed lines). 
It should be noted that this schematic drawing is thought to be an 
overview representation not claiming detailed spatial and temporal 
expression domains of single genes (for citations, see main text)
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studies have identified several chromosomal regions and 
candidate genes that are associated with the risk for schizo-
phrenia [38, 39]. However, none of the results of the link-
age studies has passed a genome-wide significance level so 
far [40]. Subsequently, a multitude of association studies 
that were recently extended by genome-wide association 
studies (GwAS) identified only a few common variants that 
contribute a very small increase in the susceptibility for 
schizophrenia [41–43]. Among the most replicable genes 
are the zinc finger binding protein 804A (ZNF804A), sev-
eral genes from the major histocompatibility (MHC) region 
on chromosome 6, neurogranin (NRGN), and TCF4 [44]. 
Most recently, several rare submicroscopic chromosomal 
alterations—called copy number variants (CNv)—have 
also been detected to cause schizophrenia or schizophre-
nia-like symptoms (e.g. as the case in 22q11-syndrome) 
[43, 44]. However, these rare chromosomal abnormalities 
cannot explain the pathogenesis of the majority of schizo-
phrenia patients and are often also associated with physical 
abnormalities and mental retardation.
Although there is evidence for enlarged ventricles and 
decreased cerebral (cortical and hippocampal) volume 
associated with schizophrenia, there is not a distinct “diag-
nostic” neuropathology associated with the disease [38, 45, 
46]. However, misplaced and clustered neurons, particu-
larly in the entorhinal cortex, indicate problems of neuronal 
migration and suggest an early developmental anomaly 
[47–49]. Moreover, pyramidal neurons in the hippocampus 
and neocortex have been shown to have smaller cell bod-
ies and fewer dendritic spines and dendritic arborisations, 
and there are also reports of decreases in cell numbers in 
the thalamus and a decreased number of oligodendrocytes 
(reviewed in [39]. Additionally, decreased presynaptic 
proteins such as synaptophysin, SNAP-25, and complexin 
II have been observed in schizophrenia brains [50, 51], as 
well as decreased density of interneurons (e.g. parvalbu-
min-immunoreactive cells; [52, 53]. Neuroimaging data 
and post-mortem studies have shown that N-acetylaspartate 
(NAA), a marker of neuronal integrity, is decreased in first 
episode and never-medicated patients [54, 55]. Based on 
these neuropathological changes, investigators have con-
ceptualised schizophrenia as a disease of functional “dys-
connectivity” [56–58], or a “disorder of the synapse” [59, 
60], affecting the machinery of the synapse and subsequent 
neurotransmission [50, 51].
Finally, accumulating evidence suggests that schizo-
phrenia might be a neurodevelopmental disorder that is—at 
least in part—caused by aberrant early brain development 
that could be partially genetically determined: (1) many 
schizophrenia patients exhibit delayed developmental 
milestones in childhood, including cognitive, motor, and 
behavioural abnormalities, which indicates abnormal brain 
function prior to diagnosis of schizophrenia, (2) obstetric 
complications and prenatal infections increase the risk for 
schizophrenia, (3) post-mortem studies did not find indica-
tors for neurodegenerative processes such as gliosis or loss 
of neurons in the brain of schizophrenia patients, and (4) 
several anatomical and functional disruptions are associ-
ated with exacerbation of schizophrenia in adulthood and 
these disruptions can be simulated in developmental ani-
mal models [61, 62]. As suggested by Murray et al. [63], 
aberrant developmental processes may play a major role, 
especially in the congenital subform of schizophrenia that 
shows a gradual increase in behavioural disturbances until 
the disorder is diagnosed in adolescence or early adult-
hood. Maynard and colleagues [64] have proposed a two-
hit hypothesis of schizophrenia. According to their sugges-
tion, a lesion occurring in early neurodevelopment (first 
hit), caused by genetic risk factors or adverse embryonic 
and perinatal events, in combination with a second hit, 
arising from hormonal events, excitotoxicity, psychosocial 
stress or oxygen radical formation, may cause schizophre-
nia. Immunocytochemical and ultrastructural post-mortem 
studies have demonstrated neuronal alterations in schizo-
phrenia, such as decreased size of the neuronal cell body, 
increased cellular packing density, fewer dendritic spines 
and synapses, and distortions in neuronal orientation [65]. 
The abnormalities in the cytoarchitecture, such as neuronal 
disarray, heterotopias and malpositioning, indicate disrup-
tion of proliferation or migration at the gestational period 
[62]. In agreement, it has consistently been shown that the 
expression of reelin, a glycoprotein that regulates neuronal 
migration, is strongly decreased in schizophrenia patients 
[66, 67]. Thus, these morphological and cytoarchitectural 
changes are likely to arise during brain maturation. In sum, 
several lines of evidence suggest that abnormalities in brain 
development may contribute to the pathogenesis of schizo-
phrenia at least in a subset of patients.
Genetic association of TCF4 with schizophrenia
For the last 14 years, chromosome 18 has been repeatedly 
proposed as a possible location for schizophrenia and bipo-
lar disorder risk genes [68–72]. As bipolar disorder and 
schizophrenia show a high genetic correlation [73], it is 
not surprising that TCF4, which is located on this chromo-
some, was initially associated with bipolar disorder: The 
first study found that bipolar disorder was associated with 
a CTG triplet repeat expansion in an intronic region of the 
TCF4 gene [74]. The second study demonstrated that mod-
erate expression of such repeats in this region was linked 
to severity of bipolar I disorder [75]. Subsequently, Pick-
ard and colleagues [72] identified a pericentric inversion of 
chromosome 18 in a small Scottish family whose members 
are suffering from mental retardation and schizophrenia, 
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and the breakpoint of this inversion was located close to the 
TCF4 gene. More recently, several large but also partially 
overlapping meta-analyses of GwAS consistently identi-
fied that common variants of the TCF4 gene contribute to 
the risk of schizophrenia (see also Table 1) [19, 76, 77]. 
In these analyses, two single nucleotide polymorphisms 
(SNPs) located in the intron between the internal exon 
4 and internal exon 5 of the human TCF4 gene, accord-
ing to the gene structure of Sepp et al. [10] (see below), 
on chromosome 18q21.2 (rs9960767, rs17512836) and 
an intragenic SNP near the TCF4 gene (rs4309482) have 
shown the strongest association with the disease [19, 76, 
77]. All three GwAS meta-analyses included data from 
the SGeNe-plus study of schizophrenia, from the Inter-
national Schizophrenia Consortium (ISC) and from the 
Molecular Genetics of Schizophrenia (MGS) group, but the 
later reports of Steinberg et al. [77] and Ripke et al. [19] 
also included additional patient and control samples that 
are not overlapping. Additionally, three more studies have 
replicated schizophrenia-TCF4 gene associations in inde-
pendent samples: (1) a study in Han Chinese (in which the 
rs9960767 SNP is not polymorphic) identified a further 
intronic TCF4 SNP (rs2958182) that showed a significant 
association with schizophrenia [78]; (2) in a discovery 
sample from Ireland and a replication sample including 
non-overlapping samples from the Psychiatric GwAS Con-
sortium (PGC), the SGeNe-plus consortium and the well-
come Trust Case Control Consortium 2 (wTCCC2), two 
intronic TCF4 SNPs (again rs9960767 and rs17594526, 
which wer among the top ten significant TCF4 SNPs in the 
so-far largest megalo-analysis of Ripke et al. [19]) passed 
the significance threshold of p < 5 × 10−8 [79]; and (3) in a 
recent family-based linkage meta-analysis, a further TCF4 
SNP was identified (rs1261117) as being significantly asso-
ciated with schizophrenia [80]. The use of the family-based 
approach is a critical advantage here, given that all other 
GwAS employed only case–control designs that are sus-
ceptible for artefacts produced by population stratification 
[81], while using nuclear families in a replication study is 
robust against population stratification-induced false-posi-
tive findings [80].
Moreover, in a phenotype-based association study 
applied to the German GRAS (Göttingen Research Associ-
ation for Schizophrenia) sample, TCF4 rs9960767 (but not 
rs4309482) displayed some signals regarding a multivari-
ate schizophrenia phenotype including PANSS positive and 
negative scores, a cognitive score, neurological soft signs, 
and age of prodromal onset [82]. Although the direction of 
the effect was similar to previous GwAS (risk allele C was 
associated with a more pronounced phenotype), the associ-
ation was not strong enough to pass multiple testing adjust-
ments. In addition, a small post-mortem study suggested 
that at least the rs9960767 SNP is neither functional nor 
affects mRNA expression in the adult human brain, indi-
cating that such polymorphisms may yield their effects on 
gene expression through post-transcriptional pathways or 
in a developmental context by gene × environment inter-
actions [41, 42]. In contrast, a more recent study reported 
that TCF4 expression level in peripheral blood was signifi-
cantly increased in patients with schizophrenia and bipo-
lar disorder compared to controls. Additionally, periph-
eral TCF4 mRNA concentration was positively correlated 
with severity of positive and negative symptoms. However, 
TCF4 expression levels were only nominal and non-signif-
icantly correlated with some TCF4 SNPs that have not so 
far been named as schizophrenia risk variants [83]. In the 
same study, after correction for multiple testing, more than 
ten TCF4 SNPs, which have not been identified in previous 
GwAS, were significantly associated with the expression 
of negative symptoms [83].
It was also investigated whether the TCF4 polymor-
phism rs9960767 modulates the response to antipsychotic 
drug treatment in schizophrenia, but in two independent 
samples, comprising more than 200 patients in total, the 
clinical improvement across 4 weeks was not influenced 
by TCF4 genotype [84], suggesting that this TCF4 SNP 
is probably not a suitable predictor for antipsychotic drug 
effects.
Taken these findings together, SNPs from the TCF4 
gene together with common variants in the major histo-
compatibility complex (MHC) region are currently the best 
replicated schizophrenia susceptibility genes. However, the 
odds ratios for single variants are still small (OR around 
1.2; see Table 1) and not useful for prediction of the dis-
order. Moreover, TCF4 SNPs cannot so far predict antip-
sychotic drug response. Thus, either TCF4 as well as the 
other schizophrenia risk genes only contribute a very small 
fraction to the total risk, together with many other genetic 
and environmental risks, or there is a distinct subpopula-
tion of patients for which the TCF4 abnormalities might be 
major contributors to the etiopathogenesis of schizophrenia.
TCF4, information processing, and cognition: human 
studies
Kraepelin [85] and Bleuler [86] proposed that attentional 
and information processing deficits constitute core symp-
toms of schizophrenia. Following the early idea of Arvid 
Carlsson that schizophrenia might be a “thalamic fil-
ter deficit disorder” [87], impairments in early informa-
tion processing have been repeatedly suggested to play a 
critical role in the pathogenesis of schizophrenia [88–91] 
Consequently, electrophysiological measures of early 
information processing—such as sensory gating or sen-
sorimotor gating—have been proposed as promising 
2820 B. B. Quednow et al.
1 3
Ta
bl
e 
1 
 
Si
ng
le
 n
uc
le
ot
id
e 
po
ly
m
or
ph
ism
s o
f t
he
 tr
an
sc
rip
tio
n 
fa
ct
or
 4
 (T
CF
4) 
ass
oc
iat
ed
 w
ith
 sc
hiz
op
hre
nia
 an
d s
ch
izo
ph
ren
ia 
en
do
ph
en
oty
pe
s
Ph
en
ot
yp
e/
en
do
ph
en
ot
yp
e
TC
F4
 S
N
Ps
Si
gn
ifi
ca
nt
 a
ss
oc
ia
tio
n 
w
ith
 m
in
or
 a
lle
le
St
ud
y 
ty
pe
 a
nd
 sa
m
pl
es
et
hn
ic
ity
R
ef
er
en
ce
s
Sc
hi
zo
ph
re
ni
a
rs
99
60
76
7
O
R 
= 
1.
20
–1
.2
3
G
w
A
S 
w
ith
 p
ar
tia
lly
 o
v
er
la
pp
in
g 
sa
m
pl
es
:
12
,9
45
–1
8,
20
6 
SZ
 p
at
ie
nt
s
34
,5
91
–4
2,
53
6 
co
nt
ro
ls
eu
ro
pe
an
 a
nc
es
try
 (a
lso
 in
clu
din
g 
eu
ro
pe
an
-A
m
er
ic
an
s a
nd
 e
u
ro
-
pe
an
 -A
us
tra
lia
ns
)
St
ef
an
ss
o
n
 e
t a
l. 
[7
6]
rs
17
51
28
36
O
R 
= 
1.
23
R
ip
ke
 e
t a
l. 
[1
9]
rs
43
09
48
2
O
R 
= 
1.
09
St
ei
nb
er
g 
et
 
al
. [
77
]
Sc
hi
zo
ph
re
ni
a
rs
29
58
18
2
O
R 
= 
0.
78
Si
ng
le
 a
ss
oc
ia
tio
n 
stu
dy
:
2,
49
6 
SZ
 p
at
ie
nt
s
5,
18
4 
co
nt
ro
ls
H
an
 C
hi
ne
se
Li
 e
t a
l. 
[7
8]
Sc
hi
zo
ph
re
ni
a
rs
99
60
76
7
O
R 
= 
1.
18
G
w
A
S:
1,
60
6 
SZ
 p
at
ie
nt
s
1,
79
4 
co
nt
ro
ls
Ir
ish
St
ra
ng
e 
et
 
al
. [
79
]
rs
17
59
45
26
a
O
R 
= 
1.
77
Sc
hi
zo
ph
re
ni
a
rs
12
61
11
7
O
R 
= 
1.
6
Fa
m
ily
-b
as
ed
 li
nk
ag
e 
m
et
a-
an
al
y-
sis
: 6
,2
98
 in
di
v
id
ua
ls 
(in
clu
din
g 
3,
28
6 
SZ
 p
at
ie
nt
s) 
fro
m 
1,8
11
 
n
u
cl
ea
r f
am
ili
es
eu
ro
pe
an
 a
nc
es
try
A
be
rg
 e
t a
l. 
[8
0]
M
ul
tiv
ar
ia
te
 sc
hi
zo
ph
re
ni
a 
ph
en
ot
yp
e 
in
cl
ud
in
g 
po
sit
iv
e,
 
n
eg
at
iv
e,
 a
n
d 
co
gn
iti
v
e 
sy
m
p-
to
m
s,
 n
eu
ro
lo
gi
ca
l s
of
t s
ig
ns
, 
an
d 
ag
e 
of
 p
ro
dr
om
al
 o
ns
et
rs
99
60
76
7
R
isk
 a
lle
le
 C
 w
as
 a
ss
o
ci
at
ed
 w
ith
 m
or
e 
pr
on
ou
nc
ed
 sc
hi
zo
ph
re
ni
a 
ph
en
ot
yp
e 
(on
ly 
tre
nd
, n
ot 
su
rvi
v
in
g 
co
rre
ct
io
n 
fo
r 
m
u
lti
pl
e 
te
sti
ng
)
Ph
en
ot
yp
e-
ba
se
d 
as
so
ci
at
io
n 
st
ud
y:
1,
04
1 
SZ
 p
at
ie
nt
s
1,
14
4 
co
nt
ro
ls
G
er
m
an
Pa
pi
ol
 e
t a
l. 
[8
2]
A
nt
ip
sy
ch
ot
ic
 d
ru
g 
re
sp
on
se
 in
 
SZ
 p
at
ie
nt
s
rs
99
60
76
7
N
o 
ef
fe
ct
Ph
ar
m
ac
og
en
et
ic
 a
ss
oc
ia
tio
n 
st
ud
y:
 2
14
 S
Z 
pa
tie
nt
s i
n 
to
ta
l 
(tw
o
 in
de
pe
nd
en
t s
am
pl
es
 w
it 
n
 
= 
70
 a
nd
 n
 
= 
14
4 
SZ
 p
at
ie
nt
s)
G
er
m
an
Le
nn
er
tz
 e
t a
l. 
[8
4]
Pr
ep
ul
se
 in
hi
bi
tio
n 
of
 th
e 
ac
ou
s-
tic
 st
ar
tle
 re
sp
on
se
 (s
en
so
ri-
m
o
to
r g
at
in
g)
rs
99
60
76
7
R
isk
 a
lle
le
 w
as
 a
ss
o
ci
at
ed
 w
ith
 sc
hi
zo
-
ph
re
ni
a-
lik
e 
en
do
ph
en
ot
yp
e
O
R 
= 
6.
82
 (S
Z)
b
O
R 
= 
4.
93
 (c
on
tro
ls)
b
O
R 
= 
4.
81
 (t
ota
l s
am
ple
)b
en
do
ph
en
ot
yp
e-
ba
se
d 
as
so
ci
a-
tio
n 
stu
dy
 in
 tw
o
 in
de
pe
nd
en
t 
sa
m
pl
es
: 1
05
 S
Z 
pa
tie
nt
s a
nd
 
hi
gh
 ri
sk
 su
bje
cts
98
 co
nt
ro
ls
SZ
 p
at
ie
nt
s: 
G
er
m
an
Co
nt
ro
ls:
 B
rit
ish
Qu
ed
no
w
 e
t a
l. 
[1
13
]
P5
0 
su
pp
re
ss
io
n 
of
 th
e a
ud
ito
ry
 
ev
o
ke
d 
po
te
nt
ia
l (
sen
so
ry 
ga
tin
g)
rs
99
60
76
7
rs
17
51
28
36
rs
17
59
79
26
a
rs
10
40
11
20
R
isk
 a
lle
le
s w
er
e 
as
so
ci
at
ed
 w
ith
 
sc
hi
zo
ph
re
ni
a-
lik
e 
en
do
ph
en
ot
yp
e
O
R 
= 
1.
23
–1
.4
6 
(ne
v
er
-
sm
o
ke
rs
)b
O
R 
= 
2.
10
–2
.4
4 
(li
gh
t s
mo
ke
rs
)b
O
R 
= 
3.
21
–5
.5
0 
(he
av
y 
sm
ok
er
s)b
O
R 
= 
1.
81
–1
.9
4 
(to
tal
 sa
mp
le)
b
en
do
ph
en
ot
yp
e-
ba
se
d 
as
so
ci
at
io
n 
st
ud
y:
 1
,8
21
 c
on
tro
ls
G
er
m
an
Qu
ed
no
w
 e
t a
l. 
[1
14
]
w
o
rd
 re
co
gn
iti
on
rs
99
60
76
7
R
isk
 a
lle
le
 C
 w
as
 a
ss
o
ci
at
ed
 w
ith
 
en
ha
nc
ed
 p
er
fo
rm
an
ce
en
do
ph
en
ot
yp
e-
ba
se
d 
as
so
ci
at
io
n 
st
ud
y:
 4
01
 S
Z 
pa
tie
nt
s
G
er
m
an
Le
nn
er
tz
 e
t a
l. 
[1
27
]
A
tte
nt
io
n 
an
d 
vi
gi
la
nc
e
w
o
rk
in
g 
m
em
or
y
Pr
oc
es
sin
g 
sp
ee
d
vi
su
o-
m
ot
or
 sp
ee
d/
se
t-s
hi
fti
ng
ve
rb
al
 fl
ue
nc
y
rs
99
60
76
7
N
o 
ef
fe
ct
en
do
ph
en
ot
yp
e-
ba
se
d 
as
so
ci
at
io
n 
st
ud
y:
19
8 
SZ
 p
at
ie
nt
s
20
5 
co
nt
ro
ls
G
er
m
an
Le
nn
er
tz
 e
t a
l. 
[8
4]
2821TCF4 and schizophrenia: neurodevelopmental functions and cognitive processing
1 3
behavioural endophenotypes of schizophrenia [92]. Such 
gating mechanisms have been conceptualised as important 
pre-attentive filter functions protecting cognitive processes 
from interfering with irrelevant information [93]. Schizo-
phrenia patients, and to a lesser extent also their unaffected 
first-degree relatives, consistently display disrupted sensory 
and sensorimotor gating, commonly demonstrated by either 
lower P50 suppression of the auditory evoked potential 
(AeP) or reduced prepulse inhibition (PPI) of the acoustic 
startle response [88, 89, 94–100]. Both measures have been 
shown to be heritable and to be disturbed before onset of 
the illness [101–107]. Although sensory (P50 suppression) 
and sensorimotor (PPI) gating are conceptually related, and 
both were in parallel suggested as useful endophenotypes 
of schizophrenia, they are not equivalent and usually also 
not correlated [94, 108–110]. However, a recent meta-anal-
ysis confirmed that electrophysiological gating measures 
differentiate best between healthy individuals, relatives of 
schizophrenia patients and the patients themselves when 
compared to other proposed endophenotypes such as ven-
tricle size, neurological soft signs or neuropsychological 
dysfunction [111].
As described above, transgenic mice moderately over-
expressing Tcf4 in the postnatal brain display profound 
reductions in sensorimotor gating as measured by PPI 
[112]. Accordingly, the impact of the schizophrenia risk 
SNP TCF4 rs9960767 on PPI was investigated in human 
samples (Table 1). In fact, the risk allele C of this SNP 
was strongly associated with reduced sensorimotor gat-
ing in two independent samples of healthy volunteers and 
schizophrenia patients [113]. Interestingly, low PPI lev-
els (>1.5 SD below normal) have shown a much stronger 
associations (OR = 4.81) with the TCF4 risk allele C than 
schizophrenia per se (OR = 1.23) [76]. when considering 
effect size measures, a similar pattern arises: whereas the 
association of a diagnosis of schizophrenia with TCF4 gen-
otype displayed only a very small effect size of w = 0.09 
[76], the association of the schizophrenia endophenotype 
PPI with TCF4 showed a strong effect size of d = 0.90 
averaged across both samples. Impressively, of the 23 sub-
jects carrying the C-allele across both investigated samples, 
14 (61 %) displayed low PPI levels (>1.5 SD below nor-
mal), when compared to the merged total sample, which is 
again an expression of the strong genotype effect of TCF4 
on PPI. The authors hypothesised that the impact on PPI 
might arise from developmental changes of brain stem 
nuclei induced by the TCF4 polymorphism (see Fig. 3, 
below, for an illustration of involved brain structures) 
[113].
Subsequently, we also investigated the influence of 21 
TCF4 polymorphisms—which were most strongly associ-
ated with schizophrenia in a recent meta-analysis [19]—on 
sensory gating as assessed by P50 suppression of the AeP GW
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[114]. we used a multi-centre study including six aca-
demic institutions throughout Germany with 1,821 subjects 
(1,023 never-smokers, 798 smokers) randomly selected 
from the general population (Table 1). Given that smok-
ing is highly prevalent in schizophrenia [115] and has been 
shown to affect sensory and sensorimotor gating [116], 
several parameters for smoking behaviour were addition-
ally assessed. Like PPI P50 suppression was also signifi-
cantly decreased in carriers of schizophrenia risk alleles 
of the TCF4 polymorphisms rs9960767, rs10401120, 
rs17597926, and 17512836—the latter two were the most 
significant SNPs in the mega-analysis of Ripke et al. [19]. 
Importantly, these gene effects were strongly modulated 
by smoking behaviour as indicated by significant interac-
tions of TCF4 genotype and smoking status: heavy smok-
ers (Fagerström score ≥4) showed stronger gene effects 
on P50 suppression than light smokers and never-smokers. 
Moreover, the genotype × smoking interaction seems to 
be dose-related as the TCF4 genotype effect grows with 
increasing smoking severity. Interestingly, TCF4 genotype 
effects on sensory gating were more evident at frontal (Fz) 
than vertex (Cz) electrodes. Previous studies have reported 
that the prefrontal cortex substantially contributes either to 
the sensory gating process per se [117] or at least to the 
generation of the P50 amplitude [118]. Additionally, data 
from a recent eeG source localization study suggest that 
the sensory gating deficit of schizophrenia patients could 
be explained by dysfunction of the dorsolateral prefrontal 
cortex [41]. Thus, TCF4 mutations (in combination with 
smoking) might affect PFC function in schizophrenia. 
Accordingly, deficits of PFC functions have recently also 
been described in Tcf4tg mice [119].
In conclusion, these results imply that the schizophrenia 
risk alleles of TCF4 variants interact with smoking behav-
iour with regard to auditory sensory gating. However, if 
smoking behaviour strongly modulates the TCF4 genotype 
effects on a proposed endophenotype of schizophrenia, it 
might also modulate the risk for schizophrenia itself. we 
therefore suggested the investigation of potential moderat-
ing effects of dimensional and binary measures of smoking 
behaviour on genetic risk factors of schizophrenia. In fact, 
preliminary data from 882 schizophrenia patients and 2,163 
controls now suggest that the risk allele C of the TCF4 
rs9960767 is indeed more frequent in smoking schizophre-
nia patients (8.3 %) than in non-smoking patients (5.3 %) 
or smoking (5.5 %) and non-smoking controls (5.8 %), 
transferring to an OR of 1.55 for smoking patients in con-
trast to OR of 0.90 for non-smoking patients (Dan Rujescu, 
University of Munich, Germany, personal communication 
of unpublished data). These results have certainly to be rep-
licated in further and larger samples, but nevertheless these 
data indicated that stratification for smoking behaviour in 
case–control association studies potentially adds power, 
resulting in stronger gene effects. Moreover, it should be 
further explored whether nicotine use itself might enhance 
the risk for schizophrenia as indicated by longitudinal stud-
ies showing that, beyond cannabis and alcohol use, early 
consumption of tobacco also increases the risk for psycho-
sis [120, 121]. Finally, an extended endophenotype, includ-
ing electrophysiological gating measures such as PPI or 
P50 suppression, smoking behaviour, and risk genes such 
as TCF4, may be suitable as an early indicator for a devel-
oping psychosis [114]. Moreover, dedicated gene × envi-
ronment studies could be performed in mouse models, 
providing additional evidence for TCF4 × smoking inter-
actions and allowing the investigation of underlying molec-
ular mechanisms.
Neurocognitive dysfunctions have also been proposed 
as promising endophenotypes of schizophrenia [122]. In 
particular, impaired verbal memory, which is among the 
most prominent and consistently reported cognitive deficits 
of schizophrenia [123], has been emphasised as a poten-
tial intermediate schizophrenia phenotype, as studies with 
unaffected relatives from multiple affected families (“mul-
tiplex families”) and twin studies demonstrated an increas-
ing memory deficit along with an increasing genetic load 
[124–126]. Lennertz et al. [127] therefore investigated the 
impact of the TCF4 rs9960767 variant on verbal memory 
performance in a sample of 401 schizophrenia patients 
[127]. while no effect of the schizophrenia risk allele C on 
immediate recall and total learning was found, a weak trend 
regarding delayed verbal memory appeared, surprisingly 
indicating superior performance in carriers of the risk allele 
compared to non-carriers. Moreover, in the cued recall con-
dition (word recognition), schizophrenia patients carrying 
at least one C-allele also significantly recognized more 
words compared to patients without the risk allele. These 
results were unexpected considering the supposed impact 
of TCF4 on brain development and assuming that an endo-
phenotype should display a similar association with the risk 
gene (e.g. impaired memory in carriers with the schizo-
phrenia risk gene) as an endophenotype with the complex 
disease phenotype (e.g. memory deficit in schizophre-
nia patients). Given that the effects sizes of the genotype 
effects were rather small (Cohen’s d = 0.34, and after cor-
rection for several covariates, d = 0.27), and that the results 
would not have become significant if the statistical thresh-
old had been corrected for multiple test parameters, these 
results should not be over-interpreted. These authors also 
explored functional effects of the same TCF4 variant on a 
comprehensive neuropsychological test battery in a sample 
of about 200 schizophrenia patients and a control sample of 
205 healthy volunteers [127]. The assessed cognitive func-
tions attention and vigilance, working memory, process-
ing speed, visuo-motor speed and set-shifting, as well as 
verbal fluency, were all unaffected by TCF4 rs9960767 in 
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both groups (unpublished data). Thus, although haploinsuf-
ficiency of the TCF4 gene is associated with severely dis-
rupted intellectual functions as presented in the PTHS, no 
considerable effect of the TCF4 rs9960767 polymorphism 
on neuropsychological function was found in this sample 
with the exception of a weak and unexpected association 
with word recognition (Table 1).
In contrast, wirgenes et al. [83] recently reported from a 
large sample of patients with schizophrenia spectrum dis-
orders (total n = 596 including patients with schizophre-
nia, bipolar disorder, other psychoses) and healthy controls 
(n = 385) that the risk alleles of the TCF4 risk variants 
rs12966547 and rs4309482 were associated with worse 
verbal fluency in the total sample. They also found some 
trends that the schizophrenia risk alleles from rs43094882 
and rs9960767 were associated with ventricular and/or hip-
pocampal volume, but these results did not survive correc-
tion for multiple testing. In the exploratory analyses, there 
were also some significant associations of other TCF4 
SNPs with verbal learning, executive functioning, and sev-
eral brain abnormalities [83].
A study in Han Chinese investigated the impact TCF4 
rs2958182 SNP, previously associated with schizophrenia 
in the same ethnicity [78], on cognitive functions in 580 
schizophrenia patients and 498 controls [128]. The authors 
reported that the schizophrenia risk allele was associated 
with better performance in patients but worse performance 
in controls regarding an IQ test as well as in attention-
related tasks. Because of this unexpected result pattern, 
the authors speculated that TCF4 and cognition might fol-
low an inverted U-shaped function. However, it is not fully 
clear at the moment whether previous european studies and 
this Chinese study can be adequately compared.
Most recently, a Canadian study explored the association 
of the TCF4 rs9960767 SNP with neurocognitive function 
in 173 first-episode psychosis patients (affective and non-
affective psychosis). The authors reported that carriers of 
the rs9960767 C allele performed worse in the cognitive 
domains of “reasoning and problem solving” and “speed of 
processing”, adumbrating that TCF4 polymorphisms might 
also contribute to deficits in higher cognitive function in 
schizophrenia patients [129].
In a lymphocyte-based gene expression study in healthy 
Mexican Americans, it has recently been shown that periph-
eral expression of TCF4—among seven further genes 
(IGFBP3, LRRN3, CRIP2, SCD, IDS, GATA3, and HN1)—
predicted cortical grey matter thickness measured by mag-
net resonance tomography [130]. Notably, TCF4 expres-
sion was particularly correlated with grey matter thickness 
in the prefrontal cortex. The authors concluded that a pro-
gressive decline in the regenerative capacity of the brain 
contributes to normal cerebral aging including thinning of 
the grey matter [130]. A critical role of TCF4 specifically 
for development of the prefrontal cortex was also supported 
by recent post-mortem data showing a significant associa-
tion between TCF4 expression and cis eSNPs (previously 
identified in an expression quantitative trait loci analysis) 
in tissue of the prefrontal cortex (rs1261085, rs1261134, 
rs1261073) and the thalamus (rs1261134), while in the hip-
pocampus, temporal cortex and cerebellum, no such asso-
ciations were found [131].
Taking the human gating and cognition data together, 
it appears that TCF4 SNPs likely affect early information 
processing in such a way that schizophrenia risk alleles 
are consistently associated with a schizophrenia-like phe-
notype, i.e. reduced gating functions (for an overview, see 
Table 1). At the least, the effect for auditory sensory gating 
was strongly modulated by smoking, suggesting a possible 
gene × environment interaction that might be also relevant 
for the development of schizophrenia. There are also ini-
tial data arguing that common TCF4 variants might have 
an impact on brain morphology specifically regarding the 
prefrontal cortex, which is also in line with the impact on 
gating functions that might involve the prefrontal cortex, 
and also in accordance with neurodevelopmental pheno-
types obtained with Tcf4 and neuronal bHLH mouse mod-
els as discussed above. whether common TCF4 variants 
also influence higher cognitive functions in healthy volun-
teers or schizophrenia patients is not clear at the moment 
as existing studies are controversial, present rather weak 
associations, and are currently not replicated. In contrast, 
more severe TCF4 mutations, as occurring in the PTHS, 
are definitely accompanied by strong cognitive dysfunc-
tion, suggesting that a considerably disturbed TCF4 func-
tion is associated with strong changes in brain development 
(see following section).
TCF4 and neurodevelopmental disorders
Heterozygous hypomorphic, null mutations or deletion 
(haploinsufficiency) of the TCF4 gene in humans causes 
the rare PTHS (an autosomal-dominant neurodevelop-
mental disorder characterized by severe mental, motor 
and language retardation, epilepsy, facial dysmorphisms, 
intermittent hyperventilation, and rarely also postnatal 
microcephaly), pointing to the fact that TCF4 is also criti-
cal for normal development of the mammalian nervous sys-
tem [132–135]. Currently, only 200–300 diagnosed cases 
with PTHS exist worldwide [134]. A small proportion of 
patients suspected to have the Angelman syndrome, which 
displays a similar phenotype as PTHS, also have mutations 
in the TCF4 gene [136]. A recent study with ten young 
PTHS patients revealed strong intellectual and motor dis-
abilities together with a behavioral phenotype that over-
laps with autism spectrum disorders [137]. The autism-like 
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behaviour was characterised by difficulties in engaging and 
communicating with others, frequent occurrence of repeti-
tive motor stereotypies, repetitive play and fascination with 
specific objects, and difficulties with changes in daily life 
routines. The real age of the PTHS patients ranged from 
32 to 289 months, whereas the estimated developmental 
age lay between 3.5 and 15 months for the mental abilities 
and between 4 and 19 months for the motor abilities [137]. 
Notably, in a recent study investigating balanced chromo-
somal abnormalities in patients with autism convergent 
genomic information, suggested that the TCF4 gene might 
also be involved in the pathogenesis of autism-spectrum 
neurodevelopmental disorders [138].
Surprisingly, prominent macroscopic brain abnormali-
ties are not common in PTHS: only subtle hypoplasia of 
the corpus callosum has been consistently reported [139–
141], while enlarged ventricles (similar to schizophrenia, 
[142]) and thin hindbrain [140, 141], as well as enlarged 
caudate nuclei and a lower hippocampus volume, have 
also been reported [143]. whalen et al. estimated that only 
about 50 % of the PTHS patients display abnormalities in 
structural brain imaging, while only about 7 % reveal a 
microcephaly [208].
Tcf4/TCF4 expression in brain development
The function of TCF4 in nervous system development and 
adult brain must be seen in the context of its numerous 
proposed and the few experimentally validated interaction 
partners of the bHLH family (see Fig. 1) and its complex 
spatio-temporally regulated expression pattern. All e-pro-
teins are expressed during embryonic stages including neu-
ral structures (http://www.brain-map.org/), with Tcf4/TCF4 
showing the highest expression levels in mouse and human 
brain tissue (http://www.brainspan.org/) [13, 144]. In con-
trast to Tcf3 and Tcf12, Tcf4 expression remains at sub-
stantially high levels in the adult and aged rodent brain 
[112, 145, 146]. Tcf4 expression is sustained particularly in 
areas of high neuronal plasticity, such as the cerebral cor-
tex, hippocampus and cerebellum [13, 112]. Human TCF4 
expression has been detected in the prosencephalon and the 
ventricular zone of the embryonic CNS [133], in the tel-
encephalon at all stages of fetal development as well and 
in the adult forebrain (http://www.brainspan.org/). In sum-
mary, TCF4 is the only e-protein being expressed at all 
stages in the developing and adult mouse and human brain.
In contrast to the constitutive and broad expression of 
Tcf4, all putative interaction partners in the nervous system 
show a much more spatio-temporally restricted expression 
profile (Fig. 1). The expression of the bHLH inhibitors 
Hes1 and Id1 are transiently expressed in embryonal stages 
and their function indeed seems to be confined to inhibit 
premature differentiation initiation [147, 148]. Neurogene-
sis-associated pro-neuronal class II bHLH proteins of the 
achaete scute (e.g. ASCL1/MASH1), atonal (e.g. ATOH1/
MATH1) and neurogenin families (NeUROG1,2) are tran-
siently expressed at early stages of development, whereas 
the gradual onset of expression of group II bHLH proteins 
involved in terminal neuronal differentiation (e.g. NeU-
ROD family members NeUROD1, -2, and -6) is confined 
to later stages and remains sustained in the adult brain [5, 
149]. All type II neuronal bHLH proteins are thought to 
depend on the hetero-dimerisation with an e-protein [1]. 
Thus, at least in later stages of neuronal differentiation 
and selected brain regions, TCF4 appears to be the obli-
gate interaction partner of neuronal class II bHLH proteins. 
This selective availability as unique interaction partner may 
explain dosage susceptibility of TCF4 observed in genetic 
model systems such as zebrafish [150] and mouse [151], 
and in human patients suffering from PTHS [134] and 
potentially also schizophrenia (see below).
Tcf4 functions in neurodevelopment and cognitive 
processing: lessons from mouse models
Tcf4 heterozygous null mutant mice (Tcf4+/−) are viable, 
fertile and display no obvious phenotype [151]. Although 
subtle defects cannot so far be excluded, Tcf4+/− mice 
do not replicate the profound effects observed in humans 
where haploinsufficiency causes severe developmen-
tal disturbances including PTHS phenotype (Fig. 2 and 
see below). As reported by Zhuang et al. [15, 152], Tcf4 
homozygous null mutant mice (Tcf4−/−) were born with 
extremely low frequency and did not survive longer than 
1 week after birth. In contrast, Flora et al. [151] did not 
observe embryonic lethality of null mutants and obtained 
expected Mendelian ratios of Tcf4−/− mice at birth; how-
ever, animals died within the first 24 h. Nevertheless, both 
studies showed that the complete inactivation of both Tcf4 
alleles has strong developmental consequences in mice 
with evident morphological defects detected so far only 
in pontine nuclei development, which has been specifi-
cally attributed to the interaction of TCF4 with the proneu-
ral transcription factor ATOH1/MATH1 [151]. Therefore, 
in mice, TCF4 function during early brain development 
may be partially compensated by the other class I bHLH 
factors, TCF3 and TCF12. However, in mosaic Tcf4+/− 
Tcf4−/− mice, only pups displaying maximal proportion 
of 30 % of Tcf4 null cells are viable [153]. Nonetheless, 
conditional knockouts enabling targeted deletions at vari-
ous stages of CNS development will be essential to better 
understand more subtle phenotypes possibly caused by the 
loss of function of Tcf4. Such mouse models may allow 
the study of embryonal TCF4 dysfunction even in the adult 
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brain without being hampered by embryonic or perinatal 
lethality.
So far, insight into the role of TCF4 on adult brain func-
tion in the mouse is restricted to a model with slightly 
increased expression levels in the forebrain [112]. In addi-
tion to loss-of-function models (see above), gain-of-func-
tion studies may be of particular relevance for schizophre-
nia, as TCF4 mRNA expression is significantly increased 
in post mortem cortical samples and peripheral blood 
cells of psychosis patients [83, 154]. Furthermore, TCF4 
mRNA expression level is elevated in neurons derived from 
human-induced pluripotential stem cells of schizophre-
nia patients versus unaffected subjects [155]. Therefore, 
Thy-1 promoter driven overexpression of Tcf4 mRNA in 
brain structures involved in cognition, such as the cortex 
and hippocampus of the mouse [112], may partially repli-
cate molecular alterations of increased schizophrenia risk 
in humans. Subsequently, we will refer to these mice as 
Tcf4tg. The onset of transgenic Tcf4 expression is confined 
to early postnatal stages, and neither breeding problems nor 
any overt abnormalities have been observed. Nonetheless, 
adult Tcf4tg mice displayed profound deficits in contextual 
and cued delay fear conditioning indicating hippocam-
pal deficits. Alterations in activity, anxiety or exploratory 
drive were not observed, thus postnatal Tcf4 overexpres-
sion affected only early information processing and cogni-
tive functions [112]. Fear-associated learning deficits were 
erased upon applying stronger aversive stimuli arguing for 
a subtle defect [112]. In addition, Tcf4tg mice display defi-
cits in trace fear memory most likely paralleled by reduced 
levels of attention and behavioural anticipation [119]. It 
has been shown that these higher order cognitive processes 
depend on both the hippocampus and the anterior cingulate 
cortex (ACC) [156]. Thus, impaired interactions between 
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Fig. 2  Phenotypical comparisons reveal different TCF4 gene dosage 
dependences in mice (a) and humans (b) in neurodevelopment related 
diseases including schizophrenia. Gain-of-function and loss-of-func-
tion analyses in mice and corresponding risk alleles and mutations in 
humans suggest that TCF4 expression differences are tolerated in a 
narrow range (range depicted in light blue). exceeding critical thresh-
olds increases disease risks (depicted in grey). Slightly increased post-
natal expression of Tcf4 has been found to cause schizophrenia (SZ)-
associated symptoms in mice. Phenotypic consequences of increased 
Tcf4 expression during embryonal stages are not yet known (a). Indi-
rect evidence from human post-mortem brain and blood sampling 
suggests that elevated expression may be associated with SZ and 
bipolar disease (BD). The critical period of enhanced TCF4 expres-
sion in humans is unknown (b). The tolerance range for reduced 
gene dosage effects might potentially be higher in mice compared to 
humans, since heterozygous animals appear to be largely unaffected, 
although a thorough behavioural phenotyping has not so far been 
performed. Thus, it is unknown if reduced gene dosage in mice may 
cause SZ-like symptoms. The analysis of null mutants is hampered 
by perinatal lethality, but structural deficits in brain development 
have already been described, although not thus far representing Pitt-
Hopkins-like symptoms (a). Loss-of-function of TCF4 (haploinsuf-
ficiency and mosaic deficiency) causes severe neurodevelopmental 
diseases including PTHS and possibly other autism-like syndromes. 
Given many examples of inverted-U-shape relationships of gene dos-
age with disease severity in autism-related neurodevelopmental dis-
eases, it appears possible that slightly reduced expression levels of 
TCF4 may be implicated in SZ (b) (for citations, see main text). SZ 
schizophrenia, BD bipolar disorder, PTHS Pitt-Hopkins Syndrome, 
NDD neurodevelopmental disorder, MR mental retardation
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the prefrontal cortex and the hippocampus likely contribute 
to the reduced cognitive performance in Tcf4tg mice. Simi-
lar disturbances between remote brain regions have been 
described in the Df(16)A+/− strain that harbour a micro-
deletion in mice corresponding to a human chromosome 22 
(22q11.2) deletion described in schizophenia [157]. Moreo-
ver, altered functional cortical–hippocampal connectiv-
ity has been frequently reported in schizophrenia patients 
[158, 159]. In addition, Tcf4tg mice display sensorimotor 
gating deficits correlating with a frequent endophenotype 
of SZ patients [88, 107, 160–162]. In summary, the analy-
sis of Tcf4tg mice has provided accumulating evidence to 
support the role of TCF4 in brain circuits involved in cog-
nition and higher order information processing, which is 
independently strengthened by human studies (Fig. 3 and 
see below).
Discussion
The schizophrenia-associated gene TCF4 belongs to a 
subfamily of bHLH transcriptional factors that recognize 
e-box binding sites on regulatory DNA elements in the 
genome [1, 8]. At early developmental stages, class I/e-
protein transcription factors such as Tcf3, Tcf4, and Tcf12 
show wide expression throughout the brain, but only Tcf4 
displays sustained expression in the adult brain of mice, 
which is most prominent in the cerebellum, hippocampus 
and cortex [112, 145]. In conclusion, TCF4 is, at least dur-
ing later stages of neurodevelopment and in the adult brain, 
the obligate interaction partner of multiple class II neuronal 
bHLH factors of, e.g., the NeUROD family [112]. There-
fore, TCF4 must be considered as an interaction ‘hub’ in 
neuronal bHLH protein networks important for different 
aspects of neurodevelopment and adult plasticity [149, 
163]. Due to potentially competing functions, it is retro-
spectively not surprising that control of TCF4 gene dos-
age and protein function, in contrast, e.g., to other neuronal 
bHLH factors, is particularly susceptible to interference. 
Thus, TCF4 availability for unknown homo- and/or heter-
odimeric bHLH complexes represents a critical bottleneck 
in neurodevelopmental processes that might be associated 
with an increased risk of schizophrenia. Reduced TCF4 
activity (haploinsuffiency) has been shown to cause severe 
mental retardation, as observable in the PTHS, and may 
also be associated with other autism-spectrum disorders in 
humans [134, 138]. More subtle gene dosage alterations are 
likely to be associated with schizophrenia and possibly also 
bipolar disease. Gene dosage sensitivity may not be as pro-
nounced in rodents compared to humans, as heterozygous 
null mutant mice display only subtle neurodevelopmental 
disturbances, although, for example, a thorough behav-
ioural analysis of these mice is still missing [151].
Given the enormous complexity of TCF4 splice variants 
and biochemical properties of different PTHS-associated 
mutations [10, 11], it is still possible that dominant-nega-
tive effects beyond dosage effects contribute to the sever-
ity of the neurodevelopmental disturbances in humans. In 
a transgenic mouse model (Tcf4tg) with slightly elevated 
expression of Tcf4 in the forebrain and displaying cognitive 
and sensorimotor deficits, such effects were observed sup-
porting the critical gene dosage sensitivity [112]. However, 
potentially dominant negative effects by the corresponding 
C-terminally tagged protein expressed in the transgenic 
animals cannot be formally excluded, since C-terminal 
frame shift mutations have been shown to alter TCF4 func-
tions [11]. Nonetheless, Tcf4tg mice display a disbalance 
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Fig. 3  Brain structures involved in postulated deficits of informa-
tion processing in mice and men. Behavioural and neuropsychologi-
cal phenotypes obtained in mice (a) and human subjects (b) suggest 
a function of TCF4 in brain networks that are important for cogni-
tion (bold lines) and sensory processing (dotted grey lines). Deregu-
lation of TCF4 expression levels during development interferes with 
proper functional connectivity within corresponding brain networks 
(for citations see main text). ACx auditory cortex, Amy amygdala, Hi 
hippocampus, NAc nucleus accumbens, PCx prefrontal cortex, PPN 
pedunculopontine nucleus, VTA ventral tegmental area, VP ventral 
pallidum
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of Neurod1 versus Id2 expression ratios, and it is thus plau-
sible that even a slight disturbance of a delicate balance 
of bHLH transcription factor gene expression in the adult 
brain impairs cognition and information processing. In line 
with that, heterozygous Neurod2 null mutants also dis-
play cognitive deficits [164]. Notably, the dominant HLH 
factors Id2 and Id4 display similar to Tcf4, Neurod2 and 
Neurod6 sustained expression in the adult brain indicating 
a dynamic control of adult TCF4 function at the level of 
dimerisation, possibly coupled to neuronal activity pos-
sibly via nuclear Ca2+ signalling. It has been shown that 
TCF4 interacts with the Ca2+ binding protein calmodulin 
at physiological concentrations inhibiting DNA binding of 
e-protein homodimers in non-neuronal cells [165–169]. 
The mode of the Ca2+-mediated regulation of TCF4 func-
tion in neurons is not known but should, for several rea-
sons, be of high interest for future attempts to understand 
the mechanisms of how TCF4 contributes to endopheno-
types of schizophrenia. Firstly, localised Ca2+ signalling 
has been identified as a key player in communicating syn-
aptic activity to the nucleus and to be critically involved in 
mediating transcription-dependent adaptive responses in 
neurodevelopment, plasticity and cognitive processes [170, 
171]. Secondly, recent cross-disorder analyses of GwAS 
data combined with pathway analysis provided strong 
evidence for the importance of l-type voltage-gated Ca2+ 
channels (vGCC) and Ca2+ signalling in schizophrenia and 
bipolar disorders [172]. Most prominently, the intronic pol-
ymorphism rs4765914 in CACNA1C has been previously 
associated independently with bipolar disorder [173, 174], 
schizophrenia [19] and major depressive disorder [175]. 
Genetic imaging approaches linked CACNA1C variants 
along an endophenotypic spectrum similar to that observed 
for TCF4 including attention deficits [176] and memory 
formation [177]. Of note, the C-terminus of CACNA1C 
encodes a transcription factor that is implicated in activity-
transcription coupling by regulated proteolysis at the mem-
brane [178]. Moreover, several other Ca2+-regulated tran-
scription factors (CReB1, MeCP2, MeF2, FOSB, NPAS4, 
CReST among others) have been associated with psychi-
atric diseases such as Rett-Syndrome, autism and bipolar 
disorder [170, 171, 179]. In addition, the validated TCF4 
interaction partners NeUROD1 and NeUROD2 are them-
selves regulated by Ca2+ [179–182]. Although there is no 
direct experimental evidence for a particular mechanism by 
which synaptic activity/Ca2+ could modulate TCF4 activity 
in neurons, several non-exclusive modes of action are pos-
sible which are based on studies with different class I and II 
bHLH factors in non-neuronal cells (see above): (1) regula-
tion of transcription or splicing of TCF4 or its interaction 
partners by Ca2+-regulated transcription or splicing fac-
tors, (2) Ca2+ controlled cytoplasm to nucleus shuttling of 
TCF4, (3) modulation of dimerization selectivity and DNA 
binding efficiency or specificity by either interaction with 
Ca2+ binding proteins such as calmodulin or posttransla-
tional modifications via Ca2+ regulated kinases, which (4) 
could also alter the recruitment of transcriptional co-factors 
such as p300/CBP, and (5) transcriptional regulation of 
gene products involved in Ca2+ signalling.
The importance of a tightly controlled gene expression 
program in the context of schizophrenia is further sup-
ported by the findings that mirR-137 is also a genetic risk 
factor and has been shown to target 3′ regions in the human 
mRNA of TCF4 [22]. Due to the promiscuity of miRs, it 
is not surprising that miR-137 most likely regulates abun-
dance levels of several mRNAs among which, however, 
may be a substantial fraction of schizophrenia risk-asso-
ciated gene products [183]. Similar to TCF4, miR-137 has 
been shown to be involved in the regulation of neuron mat-
uration [184] and adult neurogenesis [185]. Most recently, 
a post mortem study demonstrated that a decreased miR-
137 expression—caused by the TT genotype of the SNP 
rs1625579—was associated with increased TCF4 expres-
sion [154]. Although the identification of putative miR-137 
targets is mainly based on in silico predictions and has only 
partially been validated by reporter gene assays, it is pos-
sible that mir-137 also represents another ‘hub’ within gene 
regulatory programs that are considered to be of particular 
relevance for schizophrenia. Among the putative mir-137 
targets beyond TCF4 are several high confidence schizo-
phrenia risk genes (CSMD1, C10orf26, CACNA1C, and 
ZNF804A) and members of schizophrenia-associated glu-
tamatergic, GABAergic, serotonergic, and neuregulin-erbB 
signalling pathways (GRIN2A, GRM5, GABRA1, HTR2C, 
NRG2, NRG3 ERBB4) [183]. Although direct target genes 
of TCF4 in the brain are not known and putative mir-137 
targets have not been validated in vivo, growing evidence 
suggests that both factors are crucial players of gene 
expression networks that may be particularly susceptible 
to interference by environmental factors. In schizophre-
nia, multiple genes are thought to cooperate with different 
environmental factors in unfavourable combinations. Thus, 
future research should be dedicated to the elucidation of 
TCF4-and miR-137-controlled gene regulatory networks 
that may allow the elucidation of causal gene × gene inter-
actions underlying schizophrenia symptoms.
It has been proposed that the inter-individual phenotypic 
variability and severity of PTHS may reflect the molecu-
larly divergent mutations that compromise TCF4 function 
differentially [11]. Similarly, we hypothesize that a graded 
level of ‘severity’ of TCF4 dysfunction ranging from hap-
loinsufficiency caused by missense mutations in PTHS 
[134, 135], to chromosomal aberrations [138], while sub-
tle alterations induced by common genetic variants [19, 
76, 77] correlate with the ‘severity’ of the corresponding 
neurodevelopmental diseases such as mental retardation, 
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autism-spectrum disorders and schizophrenia. The most 
obvious common feature of these diseases is the graded 
intellectual and cognitive impairment. As described above, 
accumulating data from both human and mouse stud-
ies suggest that TCF4 dysfunction might be particularly 
important for higher order cognitive processing. There-
fore, it may be possible that overlapping mechanisms and/
or pathways are affected by TCF4 which could have impli-
cations for the focus of future experiments. Assuming that 
similar mechanisms are instead quantitatively altered, e.g. 
in PTHS and schizophrenia (and not categorically qualita-
tively different), the identification and validation of TCF4 
target genes in PTHS and corresponding loss-of-function 
mouse models could well be of relevance for schizophre-
nia. The genetic complexity of schizophrenia per se and the 
subtle alterations at the gene expression level that one has 
to assume to occur from the schizophrenia-associated non-
coding TCF4 variants obviously hamper the identification 
of target genes from patient-derived samples or schizophre-
nia mouse models. Therefore, the fact that different genetic 
alterations in TCF4 are causally associated with several 
phenotypically overlapping mental disorders could help 
to guide experimentally feasible attempts to obtain further 
mechanistic insights into the function of this gene. Future 
studies on TCF4 should thus not strictly focus exclusively 
on models with construct-validity for schizophrenia, which 
may be out of reach at the moment, but should (as the dif-
ferent types of mutations in the gene) step beyond disor-
der boundaries by, e.g. analysing genetically defined cellu-
lar and animal gain- and loss-of-function models in more 
depth. In addition, observations from human studies could 
foster translational studies in model systems approaching 
gene × environment interactions with relevance for schizo-
phrenia (see below).
By combining electrophysiological measurements with 
genetics, it has been shown that TCF4 risk alleles correlate 
with particular schizophrenia endophenotypes—namely 
sensory and sensorimotor gating [112–114]. Specifically 
sensory gating revealed an interesting and unexpected 
gene × environment interaction: the schizophrenia risk 
allele C of the TCF4 rs9960767 SNP was robustly associ-
ated with reduced P50 suppression of the AeP. However, 
this genotype effect was strongly modulated by smoking 
behaviour given that only smokers showed reliable TCF4-
sensory gating associations, while the gene effect was not 
present in never-smokers. Moreover, the genotype × smok-
ing interaction was dose-related, as the TCF4 genotype 
effect grows with increasing smoking severity [114]. How-
ever, the moderating influence of smoking on the TCF4 
genotype effect was not present in the previous investiga-
tion on TCF4 gene effects on sensorimotor gating meas-
ured by PPI [113]. The earlier investigated samples might 
have been too small and underpowered (healthy sample 
n = 98, schizophrenia spectrum sample n = 105) to relia-
bly examine the effects of smoking as a mediating factor on 
the TCF4 gene effects on PPI. The potentially moderating 
effect of smoking on TCF4 gene effects on PPI (and other 
schizophrenia endophenotypes) should therefore be investi-
gated in larger samples. Finally, the TCF4 genotype effect 
on PPI displayed a much stronger effect size (Cohen’s 
d = 0.90) than the mean effect on P50 suppression (mean 
d = 0.23, ranging from 0.03 in never-smokers to 0.69 in 
heavy smokers), which could be partially explained by a 
superior reliability of PPI compared to P50 suppression 
[114].
But how could the unexpected smoking × genotype 
interaction regarding P50 suppression be elucidated? 
There are at least two possible explanations: The first is 
a hidden gene × gene interaction: in this model, TCF4 
interacts with a hidden gene (or genes) so that only the 
presence of two or more risk alleles is associated with 
both smoking severity and P50 suppression, while TCF4 
alone was merely associated with P50 suppression but 
not with smoking. Further studies might investigate pos-
sible gene × gene interactions, and promising candidates 
for the “hidden” SNPs may lie in the CHRNA3-CHRNA5-
CHRNB4 gene cluster coding for α3, α5, and β4 nicotinic 
acetylcholine receptor (nAChR) subtypes. SNPs from this 
gene cluster have been reliably associated with smoking 
behaviour [186–190], and also with sensorimotor gating 
(PPI) [191] and cognitive performance [192]. The second 
and maybe more appealing explanation for the present 
result pattern could be a gene × environment interaction, 
in which smoking represents a long-lasting and ongo-
ing environmental influence. This interpretation would 
be in line with the suggestion of williams et al. [41] that 
the TCF4 schizophrenia risk allele may exert its effect 
on expression exclusively in a developmental context, 
because their post mortem data suggested that this SNP 
is neither functional nor affects mRNA expression in the 
adult human brain. However, at the moment, we can only 
hypothesise which neurobiological mechanisms might 
underlie this TCF4 × smoking interaction on P50 suppres-
sion. Using TCF4 knock-out mice, it was recently shown 
that TCF4 plays a unique role in the development of the 
pontine nuclei [151]. These nuclei are highly intercon-
nected with the cochlear nucleus and neighboring brain 
stem nuclei that are critically involved in auditory infor-
mation processing [193, 194]. Moreover, pontine nuclei 
are also connected to the pedunculopontine nucleus [195], 
which has been shown to be critically involved in auditory 
sensory gating and sensorimotor gating in animal studies 
[196–199]. Most of the auditory pathways within the brain 
stem are mediated by cholinergic neurotransmission, and 
the predominant nAChR expressed in the lower auditory 
brainstem nuclei is the α7 subtype, while α3β4 nAChR 
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also plays a role but in the development of the auditory 
brainstem system [200]. Given that repeated exposure to 
nicotine results in nAChR desensitisation [201, 202] and 
also to a long-term homeostatic increase of α4β2 and α7 
nAChR [203, 204], smoking-induced changes in brain-
stem nAChR function might interact with developmental 
changes within pontine nuclei resulting in changes of P50 
suppression. Actually, P50 amplitude to S1 was influ-
enced by smoking but not by TCF4 genotype and, there-
fore, basic auditory processing was somewhat affected by 
smoking but not directly influenced by TCF4. Moreover, 
changes in nAChR function induced by chronic nicotine 
exposure might also impact auditory sensory gating at 
neocortical or hippocampal levels [205]. Taken together, 
smoking-induced plasticity of nAChR in concert with 
neurodevelopmental changes induced by TCF4 gene vari-
ations may have affected P50 suppression in our sample. 
Alternatively, nicotine may be involved in the methylation 
of DNA sequences within the TCF4 gene or other genes 
interacting with TCF4, leading to an epigenetic change 
of the expression of the corresponding genes. It has pre-
viously been shown that nicotine could decrease glutamic 
acid decarboxylase-67 and DNA methyltransferase-1 via 
epigenetic mechanisms, which are induced by an activation 
of nAChRs located on cortical and hippocampal GABAe-
rgic interneurons [206]. Additionally, it has recently been 
demonstrated that smoking affects monoaminooxidase-
A (MAOA) promoter methylation in DNA prepared from 
lymphoblasts and whole blood [207]. Interestingly, quit-
ting smoking did not lead to a return to methylation lev-
els found in never-smokers, indicating a long-lasting 
effect of smoking on DNA methylation. Thus, smoking 
might exert a sustained impact on central MAOA activity 
(and other genes) via epigenetic mechanisms, leading to 
changes in noradrenergic function that interact with neu-
rodevelopmental changes caused by TCF4 gene variations 
(see above). eventually, nicotine might also impact the 
expression of TCF4 gene directly with functional conse-
quences on early information processing. In summary, the 
unexpected findings in humans of TCF4 × smoking inter-
actions has inspired the formulation of several hypotheses 
linking different biological systems as additional modula-
tors of TCF4-associated endophenotypes i.e. information 
processing and cognition. These, in turn, could be further 
investigated in Tcf4tg mice which display complemen-
tary endophenotypes and may offer predictive value for 
validation and possible pre-clinical studies [112, 119]. 
Ameliorating the cognitive impairments in schizophrenia, 
most likely caused by higher order information-processing 
deficits in dispersed brain circuits, still represents a criti-
cal unmet medical need to finally improve the therapeutic 
options for most schizophrenic patients. The elucidation of 
dedicated TCF4 risk variant-associated endophenotypes 
and corresponding molecular mechanisms certainly repre-
sents the first steps towards this goal.
Conclusions
TCF4 is still one of the most promising schizophrenia risk 
genes, as it is slightly but replicably associated with the 
illness, is more strongly related to gating endophenotypes 
of schizophrenia, and seems to be susceptible to environ-
mental impact, as discussed above. Moreover, it obvi-
ously plays an important role in brain development and 
is connected to the function of other genes such as miR-
137, which are also discussed as schizophrenia risk genes. 
Taken together, a causal role of TCF4 for schizophrenia 
would be in line with neurodevelopmental hypotheses 
as well as with repeated-hit models and G × e interac-
tion models. Thus, TCF4 as a schizophrenia risk gene 
would be versatile model that has the potential to inte-
grate several schizophrenia models previously suggested. 
However, the small gene effects in large schizophrenia 
patient populations and the stronger gene effects regard-
ing gating endophenotypes might indicate that there is a 
subgroup of patients in which TCF4 plays a major role 
during pathogenesis, while most of the patients have dif-
ferent pathogenic pathways. Thus, future research might 
accomplish the identification of a specific TCF4-lead 
schizophrenia by combining genotying and (endo)pheno-
typing. Finally, it is also conceivable that a combination 
of risk genes ranging from the TCF4 associated bHLH 
system, including interaction partners and target genes as 
well as associated regulatory mechanisms such as miR-
137 and possibly Ca2+ linked signalling networks, could 
represent a ‘TCF4 gene set’ regulating neuronal growth 
and differentiation in a highly redundant network. These 
genes might cooperatively be responsible for the patho-
genesis within a subgroup of schizophrenia patients. Due 
to the high functional redundancy in this network, a criti-
cal mass of genetically and environmentally induced dys-
function is needed before the systems breaks down. Thus, 
we might focus on gene sets within the bHLH system and 
neighbouring regulatory systems to identify patients with 
a strong genetic and developmental pathogenesis. A pos-
tulated TCF4-associated network of risk factors might 
potentially be suitable as an early indicator for a schizo-
phrenic subtype. when combined with electrophysiologi-
cal gating measures (such as PPI or P50 suppression), 
smoking behaviour and cognitive performance, corre-
sponding molecular profiling could guide future stratified 
sub-population-directed therapies.
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